Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia

Mentese, Ahmet; Demir, Selim; ERKUT, NERGİZ; OZER YAMAN, SERAP; Alver, Ahmet; Sumer, Aysegul; ERDEM, SENIZ; Sönmez, Mehmet Emin

Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia

Ahmet MENTEŞE, (Karadeniz Technical University Vocational School of Health Sciences, Program of Medical Laboratory Techniques, Trabzon, Turkey)

Nergiz ERKUT, (Karadeniz Technical University Faculty of Medicine, Department of Hematology, Trabzon, Turkey)

Selim DEMİR, (Karadeniz Technical University Faculty of Health Sciences, Department of Nutrition and Dietetics, Trabzon, Turkey)

Serap OZER YAMAN, (Karadeniz Technical University Faculty of Medicine, Department of Medical Biochemistry, Trabzon, Turkey)

Ayşegül SÜMER, (Recep Tayyip Erdoğan University Faculty of Health Services, Department of Nursing, Rize, Turkey)

Şeniz DOĞRAMACI, (Karadeniz Technical University Faculty of Medicine, Department of Medical Biochemistry, Trabzon, Turkey)

Ahmet ALVER, (Karadeniz Technical University Faculty of Medicine, Department of Medical Biochemistry, Trabzon, Turkey)

Mehmet SÖNMEZ (Karadeniz Technical University Faculty of Medicine, Department of Hematology, Trabzon, Turkey)

Turkish Journal of Hematology

0 0

Yıl: 2017 Cilt: 34 Sayı: 4 Sayfa Aralığı: 307 - 313 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia

Öz:

Amaç: Kanser, dünyadaki başlıca ölüm nedenlerinden birisi olup, küresel bir toplum sağlığı sorunudur. Organizmanın kendi antijenlerine karşı gelişen otoantikorlar pek çok kanser hastasının serumunda tespit edilmiştir. Son yıllarda karbonik anhidraz (KA) I ve II otoantikorlarının varlığı bazı otoimmün hastalıklarda ve kanser türlerinde gösterilmiştir, ancak bu immün yanıtın altında yatan mekanizmalar henüz açıklanabilmiş değildir. Bu çalışmanın amacı, akut miyeloid lösemili (AML) kişilerde, KA I ve II otoantikorlarının varlığını değerlendirmek ve hastalığın otoimmün temeline dair yeni bir bakış açısı sağlamaktır. Gereç ve Yöntemler: Otuz hasta ve 30 sağlıklı kontrolden elde edilen serum örneklerinde anti-KA I ve II antikor düzeyleri ELISA yöntemiyle belirlendi. Bulgular: AML grubundaki anti-KA I ve II antikor düzeyleri kontrol grubu (p= sırasıyla 0,0001 ve 0,018) ile karşılaştırıldığında anlamlı derecede yüksek bulundu. Ayrıca KA I ve II otoantikor seviyeleri arasında güçlü bir pozitif korelasyon saptandı (r=0,613; p=0,0001). Sonuç: Elde edilen sonuçlar bu otoantikorların AML patogenezinde rolü olabileceğini düşündürmektedir. Kesin mekanizmayı ortaya çıkarabilmek için daha kapsamlı çalışmalar gereklidir.

Anahtar Kelime:

Konular: Hematoloji

Akut Miyeloid Lösemi Hastalarında Karbonik Anhidraz I ve II Otoantikorları

Öz:

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011;152:524-542.
3. Erkut N, Menteşe A, Özbaş HM, Ermantaş N, Sümer A, Örem A, Sönmez M. The prognostic significance of soluble urokinase plasminogen activator receptor in acute myeloid leukemia. Turk J Hematol 2016;33:135-140.
4. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433-441.
5. Ortona E, Pierdominici M, Berstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. J Steroid Biochem Mol Biol 2014;144(Pt B):260-267.
6. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, Wiewrodt R, Barnes AC, Robertson JF. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008;63:228- 233.
7. Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, Zhang XG, Gao X, Hu W, Yen Y, Kernstine KH. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 2008;10:R40.
8. Lowe FJ, Shen W, Zu J, Li J, Wang H, Zhang X, Zhong L. A novel autoantibody test for the detection of pre-neoplastic lung lesions. Mol Cancer 2014;13:78.
9. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-181.
10. Gokcen T, Gulcin I, Ozturk T, Goren AC. A class of sulfonamides as carbonic anhydrase I and II inhibitors. J Enzyme Inhib Med Chem 2016;31(Suppl 2)180-188.
11. Leppilampi M, Koistinen P, Savolainen ER, Hannuksela J, Parkkila AK, Niemelä O, Pastoreková S, Pastorek J, Waheed A, Sly WS, Parkkila S, Rajaniemi H. The expression of carbonic anhydrase II in hematological malignancies. Clin Cancer Res 2002;8:2240-2245.
12. Menteşe A, Erkut N, Sümer A, Us Altay D, Alver A, Sönmez M. Anti-carbonic anhydrase antibodies in iron deficiency anemia. Hematology 2015;20:363- 367.
13. Alver A, Şentürk A, Çakirbay H, Menteşe A, Gökmen F, Keha EE, Uçar F. Carbonic anhydrase II autoantibody and oxidative stress in rheumatoid arthritis. Clin Biochem 2011;44:1385-1389.
14. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 2009;8:410- 414.
15. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 2013;121:2424-2431.
16. Werner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer 2015;136:2243-2252.
17. Woodard KM, Chapman CJ. Lung cancer - can autoantibodies provide an aid to diagnosis? Expert Opin Med Diagn 2008;2:911-923.
18. Kino-Ohsaki J, Nishimori I, Morita M, Okazaki K, Yamamoto Y, Onishi S, Hollingsworth MA. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren’s syndrome. Gastroenterology 1996;110:1579-1586.
19. Alver A, Mentese A, Karahan SC, Erem C, Keha EE, Arikan MK, Eminağaoğlu MS, Deger O. Increased serum anti-carbonic anhydrase II antibodies in patients with Graves’ disease. Exp Clin Endocrinol Diabetes 2007;115:287- 291.
20. Aliyazicioglu R, Guven S, Mentese A, Kolayli S, Cengiz S, Deger O, Alver A. Serum anti-carbonic anhydrase II antibodies and oxidant-antioxidant balance in pre-eclampsia. Am J Reprod Immunol 2011;66:297-303.
21. Alver A, Menteşe A, Menteşe U, Sümer A, Uçar F, Us Altay D. Anti-carbonic anhydrase II antibodies in end-stage renal disease patients. Med Princ Pract 2014;23:331-335.
22. Yang J, Schiffer CA. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? Expert Rev Hematol 2012;5:395-407.
23. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-143.
24. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R; Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006;13:682-690.
25. Cho-Chung YS. Autoantibody biomarkers in the detection of cancer. Biochim Biophys Acta 2006;1762:587-591.
26. Erkut N, Mentese A, Ozbas HM, Sumer A, Orem A, Topbas M, Sonmez M. The indicator of hypoxia in acute leukemia: ischemia-modified albumin. Cancer Biomark 2015;15:559-565.
27. Bai J, He A, Zhang W, Huang C, Yang J, Yang Y, Wang J, Zhang Y. Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling. Proteome Sci 2013;11:39.
28. Wu F, Oka Y, Tsuboi A, Elisseeva OA, Ogata K, Nakajima H, Fujiki F, Masuda T, Murakami M, Yoshihara S, Ikegame K, Hosen N, Kawakami M, Nakagawa M, Kubota T, Soma T, Yamagami T, Tsukaguchi M, Ogawa H, Oji Y, Hamaoka T, Kawase I, Sugiyama H. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 2005;19:268-274.
29. Kostiala AA, Gripenberg M, Elonen E, Gripenberg G, Kostiala I. Follow-up of antibodies against single-stranded DNA in patients with haematological malignancies. Clin Exp Immunol 1985;61:15-23.
30. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Zaccari G, Papa G. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Thromb Haemost 1993;70:568-572.
31. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003;106:224-231.
32. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, Schmitt M. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002;30:1029-1035.
33. Chen G, Zhang W, Cao X, Li F, Liu X, Yao L. Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res 2005;29:503- 509.
34. Karahan SC, Guven S, Mentese A, Bacak A, Kopuz M, Ozeren M. Serum anticarbonic anhydrase I and II antibodies and idiopathic recurrent pregnancy loss. Reprod Biomed Online 2009;19:859-863.
35. Turk A, Aykut M, Akyol N, Kola M, Mentese A, Sumer A, Alver A, Erdol H. Serum anti-carbonic anhydrase antibodies and oxidant-antioxidant balance in patients with acute anterior uveitis. Ocul Immunol Inflamm 2014;22:127-132.
36. Demir C, Demir H, Esen R, Atmaca M, Tagdemir E. Erythrocyte catalase and carbonic anhydrase activities in acute leukemias. Asian Pac J Cancer Prev 2010;11:247-250.
37. Parkkila S, Lasota J, Fletcher JA, Ou WB, Kivelä AJ, Nuorva K, Parkkila AK, Ollikainen J, Sly WS, Waheed A, Pastorekova S, Pastorek J, Isola J, Miettinen M. Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 2010;23:743-750.
38. Iuchi Y, Okada F, Onuma K, Onoda T, Asao H, Kobayashi M, Fujii J. Elevated oxidative stress in erythrocytes due to a SOD1 deficiency causes anaemia and triggers autoantibody production. Biochem J 2007;402:219-227.
39. Iuchi Y, Okada F, Takamiya R, Kibe N, Tsunoda S, Nakajima O, Toyoda K, Nagae R, Suematsu M, Soga T, Uchida K, Fujii J. Rescue of anaemia and autoimmune responses in SOD1-deficient mice by transgenic expression of human SOD1 in erythrocytes. Biochem J 2009;422:313-320.
40. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, Colombo R, Rossi R, Milzani A. Proteins as biomarkers of oxidative/ nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005;24:55-99.
41. Amara A, Constans J, Chaugier C, Sebban A, Dubourg L, Peuchant E, Pellegrin JL, Leng B, Conri C, Geffard M. Autoantibodies to malondialdehydemodified epitope in connective tissue diseases and vasculitides. Clin Exp Immunol 1995;101:233-228.
42. Toyoda K, Nagae R, Akagawa M, Ishino K, Shibata T, Ito S, Shibata N, Yamamoto T, Kobayashi M, Takasaki Y, Matsuda T, Uchida K. Protein-bound 4-hydroxy-2-nonenal: an endogenous triggering antigen of antI-DNA response. J Biol Chem 2007;282:25769-25778.
43. Uchida K, Hasui Y, Osawa T. Covalent attachment of 4-hydroxy-2-nonenal to erythrocyte proteins. J Biochem 1997;122:1246-1251.
44. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
45. Cvetkovic JT, Wallberg-Jonsson S, Ahmed E, Rantapaa-Dahlqvist S, Lefvert AK. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:988-995.
46. Ben Mansour R, Lassoued S, Elgaied A, Haddouk S, Marzouk S, Bahloul Z, Masmoudi H, Attia H, Aïfa MS, Fakhfakh F. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010;39:247-253.
47. Winyard PG, Ryan B, Eggleton P, Nissim A, Taylor E, Lo Faro ML, Burkholz T, Szabó-Taylor KE, Fox B, Viner N, Haigh RC, Benjamin N, Jones AM, Whiteman M. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem Soc Trans 2011;39:1226-1232.
48. Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, Yang HY, Tian W, Meng X, Zhang H, Chen SP. Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem 2010;285:15010-15015.

APA	Mentese A, ERKUT N, Demir S, OZER YAMAN S, Sumer A, ERDEM S, Alver A, Sönmez M (2017). Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. , 307 - 313.
Chicago	Mentese Ahmet,ERKUT NERGİZ,Demir Selim,OZER YAMAN SERAP,Sumer Aysegul,ERDEM SENIZ,Alver Ahmet,Sönmez Mehmet Emin Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. (2017): 307 - 313.
MLA	Mentese Ahmet,ERKUT NERGİZ,Demir Selim,OZER YAMAN SERAP,Sumer Aysegul,ERDEM SENIZ,Alver Ahmet,Sönmez Mehmet Emin Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. , 2017, ss.307 - 313.
AMA	Mentese A,ERKUT N,Demir S,OZER YAMAN S,Sumer A,ERDEM S,Alver A,Sönmez M Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. . 2017; 307 - 313.
Vancouver	Mentese A,ERKUT N,Demir S,OZER YAMAN S,Sumer A,ERDEM S,Alver A,Sönmez M Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. . 2017; 307 - 313.
IEEE	Mentese A,ERKUT N,Demir S,OZER YAMAN S,Sumer A,ERDEM S,Alver A,Sönmez M "Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia." , ss.307 - 313, 2017.
ISNAD	Mentese, Ahmet vd. "Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia". (2017), 307-313.

APA	Mentese A, ERKUT N, Demir S, OZER YAMAN S, Sumer A, ERDEM S, Alver A, Sönmez M (2017). Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Hematology, 34(4), 307 - 313.
Chicago	Mentese Ahmet,ERKUT NERGİZ,Demir Selim,OZER YAMAN SERAP,Sumer Aysegul,ERDEM SENIZ,Alver Ahmet,Sönmez Mehmet Emin Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Hematology 34, no.4 (2017): 307 - 313.
MLA	Mentese Ahmet,ERKUT NERGİZ,Demir Selim,OZER YAMAN SERAP,Sumer Aysegul,ERDEM SENIZ,Alver Ahmet,Sönmez Mehmet Emin Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Hematology, vol.34, no.4, 2017, ss.307 - 313.
AMA	Mentese A,ERKUT N,Demir S,OZER YAMAN S,Sumer A,ERDEM S,Alver A,Sönmez M Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Hematology. 2017; 34(4): 307 - 313.
Vancouver	Mentese A,ERKUT N,Demir S,OZER YAMAN S,Sumer A,ERDEM S,Alver A,Sönmez M Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Hematology. 2017; 34(4): 307 - 313.
IEEE	Mentese A,ERKUT N,Demir S,OZER YAMAN S,Sumer A,ERDEM S,Alver A,Sönmez M "Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia." Turkish Journal of Hematology, 34, ss.307 - 313, 2017.
ISNAD	Mentese, Ahmet vd. "Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia". Turkish Journal of Hematology 34/4 (2017), 307-313.